These results suggest that the interaction between DREAM and PS2 may represent a new target for modulation of PS2 processing, which could have therapeutic potential in Alzheimer’s disease (AD) treatment. The gene discussed is KCNIP3; the disease is early-onset autosomal dominant Alzheimer disease.